Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease

Movement Disorders

Volumn 14, Issue 1, 1999, Pages 117-121

  Pappert, Eric J ^a   Goetz, Christopher G ^a   Niederman, Francie G ^a   Raman, Rema ^a   Leurgans, Sue ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dream phenomenon; Hallucinations; Illusions; Parkinson's disease; Sleep fragmentation

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ARTICLE; DREAMING; FEMALE; HALLUCINATION; HUMAN; ILLUSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DISORDER; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DELUSIONS; DREAMS; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SLEEP DISORDERS;

EID: 0032961733     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0     Document Type: Article

References (16)

1. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study [Abstract]. Neurology 1983;14:136.
2. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996;53:1265-1268.
3. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa infusions in severely hallucinating Parkinson's disease patients: high dose pharmacologic challenge does not precipitate hallucinations. Neurology 1998;50:515-517.
4. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:92-98.
5. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
6. Kales A, Ansel RD, Markham CH, Sharf MB, Tan T. Sleep in patients with Parkinson's disease and in normal subjects prior to and following levodopa administration. Int J Clin Pharmacol Ther 1971;12:397-406.
7. Sharf B. Moskovitz CH, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978;43:143-151.
8. Nausieda PA, Giantz R, Weber S, Baum R, Klawans HL. Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 1984;40:271-277.
9. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
10. Rothenberg SA. Measurement of sleep fragmentation. In: Peter JH, Pedszus T, Van Wichert P, eds. Sleep-Related Disorders and Internal Diseases. New York, NY: Springer-Verlag, 1987:63-78.
11. Andreason NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1984.
12. Steriade M, McCarley RW. Brainstem Control of Wakefulness and Sleep. New York, NY: Plenum Press, 1990.
13. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm 1975;37: 175-182.
14. Zoldan J, Friedberg G, Weizrnan A, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 antagonist. Neurology 1995;45:1305-1308.
15. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219-1221.
16. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S, Stebbins GT. Severity and temporal stability of hallucinations/illusions in Parkinson's disease: prospective, longitudinal study [Abstract]. Neurology 1997;48:A370.